Saskatchewan Health to Cover Dexcom G6 Continuous Glucose Monitoring System for People with Diabetes under the age of 18

  • Dexcom CGM use is proven to improve glycemic control1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring.3

BURNABY, BC, June 1, 2021 /CNW Telbec/ - Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes under the age of 18 living in Saskatchewan may now receive provincial coverage for the Dexcom G6 CGM System through Saskatchewan Health. This coverage expansion is in line with Dexcom's mission to make it easier for people living with diabetes to experience the benefits of using a CGM system for their diabetes management. 

Saskatchewan today joins Yukon and Quebec to offer public coverage of CGM systems under provincial health plans. In addition, Prince Edward Island and Manitoba have also recently announced plans for funding based on their 2021 budget platforms. Today's announcement marks a significant accomplishment in increasing access to life-changing technology used in the management of diabetes and recognizes the impact that CGM technology can have on those living with this complex condition.

"Access to CGM demonstrates the province of Saskatchewan's commitment to improving the health of people living with diabetes and giving caregivers greater visibility to what's happening with their child's glucose levels. With a condition that changes every day and can be unpredictable, CGM can be a game-changer for the whole family," says Laura Endres, Vice President and General Manager of Dexcom Canada.

The Dexcom G6 CGM System includes a small, wearable sensor that measures glucose just below the skin; a transmitter to continuously and wirelessly send glucose levels to a display device; and a compatible smart device* or receiver that displays real-time glucose data to users without the need for fingersticks or scanning. And with real-time alerts, including a predictive Urgent Low Soon alert, the Dexcom G6 can warn the user in advance of hypoglycemia — allowing time to take appropriate action before it happens — day or night. When using the Dexcom Follow App, parents can also access their child's glucose levels remotely and be alerted if they are going out of range.

"When Mathew was diagnosed with type 1 diabetes, our family was devastated, exhausted, and truthfully so heartbroken about what that diagnosis could mean for him in his life," says Saskatoon resident Cindy Voss, whose 13-year-old son lives with diabetes. "We were blind to what was going on in his body and felt completely powerless. Since Mathew started using the Dexcom G6 CGM System, it gave our family more confidence in managing his condition and greater peace of mind with the alerts and the Follow app ‡. We are so happy that other families in Saskatchewan will now be able to access this technology that has made such a difference in our lives."  

As part of the Saskatchewan Health coverage program, users will now also be able to pick up their Dexcom CGM supplies directly through their local pharmacy.

For more information about the coverage criteria for Saskatchewan Health and the process for getting started, please visit https://www.dexcom.com/en-CA/public-coverage.

About Dexcom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
* For a list of compatible devices, please visit dexcom.com/compatibility
 Following requires the Dexcom Follow App and an Internet connection. Followers should always confirm readings on the Dexcom G6 App or Receiver before making treatment decisions.

References
_______________________________

1 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.

2 Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2019;21(3):128-32.

3 Roze S, Isitt J, Smith-Palmer J, Lynch P. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor Versus Self Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. Poster presentation presented at: 2020 Canadian Association for Population Therapeutics; October 27, 2020.

 

SOURCE Dexcom, Inc.